Loading…
← CockpitCompetitor Analysis › 600572.SS Zhejiang CONBA Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang CONBA Pharmaceutical Co., Ltd. Class A600572.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang pharma group selling probiotics, plant-based drugs and other OTC and prescription health products.

≈ A diversified Chinese Bayer Consumer HealthMomentum leader 80
Mkt cap
$1.52B
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$26.1M
20-day average traded
Fwd P/E
16.0×
forward earnings
ROIC−WACC
+4.4 pp
WACC 5.4%
Hurdle
-8 pp
Req g minus delivered
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥4.15
1D-0.7%
1W-0.9%
1M-3.7%
3M-11.3%
6M-3.7%
YTD-7.0%
1Y-12.1%
ATR %2.2%
52w lowhigh19.7% off high

What Zhejiang CONBA Pharmaceutical does

Zhejiang pharma group selling probiotics, plant-based drugs and other OTC and prescription health products.

In one line: A diversified Chinese Bayer Consumer Health.

Products and services

  • Probiotic supplements
  • Plant-based prescription drugs
  • OTC cold/digestive products

Customers

  • Retail pharmacies
  • Hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • OTC and prescription drugs
  • Probiotics and plant extracts

What could go right

  • Consumer health and self-medication trend
  • Probiotics category growth

What could go wrong

  • OTC price competition
  • Regulatory scrutiny of health claims

Moat: narrow (brand, distribution). Established OTC and probiotic brands with broad pharmacy distribution across China.

Headquarters: Hangzhou, China · Employees: 7,826

Named competitors

Zhejiang CONBA Pharmaceutical at a glance

Size Zhejiang CONBA Pharmaceutical (600572.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.52B, the 1497th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.15 on 18 Nov 2026.

Performance Over six months the shares fell 3.7%, against -14.5% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 4.1% over the last twelve months (peer median +3.6%); the operating margin is 9.4% (peer median 10.4%).

Valuation It trades at 16.0× forward earnings against a peer median of 28.1× (4th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.4 points above its cost of capital (5.4% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026600572.SS 97Peer median 87
Six months, rebased to 100: Zhejiang CONBA Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang CONBA Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.83BCN¥6.42BCN¥6.44BCN¥6.65BCN¥5.93B
Revenue growth—0%-3%+12%—
Gross profitCN¥3.93BCN¥3.27BCN¥3.27BCN¥3.72BCN¥3.37B
EBITDAn/aCN¥858MCN¥907MCN¥1.01BCN¥966M
Net incomeCN¥457MCN¥474MCN¥622MCN¥592MCN¥358M
Free cash flowCN¥1.04BCN¥830MCN¥754MCN¥712MCN¥892M
Capital expenditureCN¥224MCN¥147MCN¥291MCN¥209MCN¥292M
Total debtCN¥354MCN¥506MCN¥625MCN¥1.36BCN¥1.23B

Quarterly statements and history in the cockpit →

Zhejiang CONBA Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%603235298380SRPT141080CORONA002019002675JUBLPHARMA600420002755301047002626ANURASPAHCASTRAZEN000766140410310210MARKSANS4516600572.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang CONBA Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%20×40×60×CORONA002019002675JUBLPHARMA600420002755301047002626ANURASPAHCMARKSANS4516600572.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang CONBA Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%603235SRPTCORONA002675600420002755301047PAHCASTRAZEN000766MARKSANS4516600572.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang CONBA Pharmaceutical is the large dot.

Zhejiang CONBA Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600572.SS vs 300146.SZ vs 000999.SZ vs 000538.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang CONBA Pharmaceutical 600572.SS$1.52B-4%+4%9%16.0×-6.1%
By-health 300146.SZ$2.56B-1%+10%11%24.7×4.8%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%

How Zhejiang CONBA Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang CONBA Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600572.SSPeer medianRank in peer set
1-month return-3.7%-5.8%9th highest of 21
6-month return-3.7%-14.5%8th highest of 21
Distance from 52-week high-19.7%-40.5%6th highest of 21
Revenue growth (TTM)+4.1%+3.6%11th highest of 21
Operating margin9.4%10.4%10th lowest of 21
Forward P/E16.0×28.1×4th cheapest of 13
Growth the price implies (Req g, 7 yrs)-6.1%9.4%5th least demanding of 13
Growth delivered (Del g)+1.9%+4.0%7th highest of 13
Hurdle (Req g minus delivered)-8.0 pp+12.4 pp4th least demanding of 13
ROIC minus cost of capital+4.4 pp-1.3 pp7th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%n/an/an/a
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%58.9×36.3%+16.6%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%27.2×n/an/a
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%9.9×-6.4%+12.7%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%n/an/an/a
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%n/an/an/a
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%23.2×31.0%+16.6%
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%7.9×-18.1%+7.0%

Questions

Who are Zhejiang CONBA Pharmaceutical's main competitors?
Named competitors: By-health (300146.SZ), China Resources Sanjiu (000999.SZ), Yunnan Baiyao (000538.SZ). The cockpit's measured peer set (industry) also includes JiangXi Tianxin Pharmaceutical (603235.SS), ABL Bio (298380.KS), Sarepta Therapeutics (SRPT), LigaChem Biosciences (141080.KS), Corona Remedies (CORONA.NS), Yifan Pharmaceutical (002019.SZ).
Is Zhejiang CONBA Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 16.0× against a peer median of 28.1×, 4th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Zhejiang CONBA Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -3.7% against -14.5% for the median peer; over one year -12.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.